The Food and Drug Administration (FDA) has approved Qternmet XR (AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).
Qternmet XR is a combination product that contains dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Initiation with Qternmet XR is intended only for patients currently taking metformin.